Top Page
Trellus Health PLC
(LSE:TRLS)
Trellus Health PLC (TRLS) vs. iShares MSCI United Kingdom ETF (EWC)
Trellus Health PLC Business Overview & Revenue Model
Trellus Health PLC Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 359.00K | 114.00K | 19.00K | 18.00K | 25.00K | 0.00 |
| Gross Profit | 359.00K | 114.00K | 19.00K | 18.00K | 25.00K | 0.00 |
| EBITDA | -6.93M | -7.16M | -6.50M | -8.27M | -5.87M | -1.52M |
| Net Income | -6.89M | -7.78M | -6.34M | -8.81M | -5.90M | -1.52M |
Balance Sheet | ||||||
| Total Assets | 9.22M | 12.14M | 20.29M | 25.91M | 36.80M | 4.37M |
| Cash, Cash Equivalents and Short-Term Investments | 1.57M | 4.34M | 12.17M | 19.09M | 31.98M | 3.68M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 513.00K | 371.00K | 786.00K | 822.00K | 1.52M | 122.00K |
| Stockholders Equity | 8.71M | 11.77M | 19.50M | 25.09M | 35.27M | 4.25M |
Cash Flow | ||||||
| Free Cash Flow | -6.16M | -7.86M | -7.63M | -11.53M | -8.49M | -1.32M |
| Operating Cash Flow | -6.16M | -7.32M | -5.27M | -8.62M | -4.77M | -1.30M |
| Investing Cash Flow | -291.00K | -540.00K | -2.35M | -2.91M | -3.72M | -1.35M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 38.52M | 10.02M |
Trellus Health PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | £10.89M | -6.32 | -15.57% | ― | 13.32% | 55.07% | |
58 Neutral | £11.35M | -0.31 | -122.54% | ― | -57.03% | -15.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £646.03K | -0.12 | -56.95% | ― | ― | ― | |
38 Underperform | £10.43M | -0.26 | -407.49% | ― | 72.17% | 79.03% |
Trellus Health PLC Corporate Events
Trellus Health plans to raise up to £5 million via a 12‑month secured convertible loan note facility from an institutional investor, with warrants attached and funds available in staged tranches, subject to shareholder approval at a general meeting on 20 January 2026. The financing is designed to extend the company’s cash runway, with the first two tranches expected to fund operations until late Q1 2026, support ongoing commercial initiatives and partnership discussions, and provide flexibility over the timing and scale of capital drawdowns, but the board warns that failure to secure shareholder backing or alternative funding would likely result in the company ceasing to be a going concern and entering administration.
Trellus Health PLC has entered into an unsecured loan agreement with its substantial shareholder, Icahn School of Medicine at Mount Sinai, for $600,000 to support its commercial strategy and extend its cash runway to January 2026. The loan, which is non-interest bearing for the first six months, will help the company focus on securing additional commercial contracts with pharmaceutical companies and CROs, with recent contracts signed with two leading global CROs to implement trials by year-end.
Trellus Health PLC has signed a 12-month contract with a leading global clinical research organization to utilize its Trellus TrialSet™ offering, focusing on immunology and inflammation. This marks the company’s second contract with a major CRO, reinforcing its strategic growth in the clinical trials sector. The contract includes upfront, monthly, and milestone payments, and is structured around key performance indicators to optimize trial recruitment and reduce screen failure rates. This development highlights Trellus Health’s growing recognition in the pharmaceutical sector, although it does not immediately extend the company’s cash runway beyond December 2025.
Trellus Health PLC has signed a 12-month contract with a leading global clinical research organization to utilize its Trellus TrialSet™ offering, focusing on immunology and inflammation for two late-stage clinical trials. This contract, which includes various performance-based fees, marks the company’s second agreement with a major CRO, underscoring the strategic importance of the clinical trials sector for Trellus Health. While the contract does not immediately extend the company’s financial runway, it highlights the growing recognition of Trellus Health’s value in the pharmaceutical sector.
Trellus Health PLC has signed a 12-month contract with a leading global Clinical Research Organisation (CRO) to enhance recruitment and enrollment for a mid-stage clinical trial in immunology and inflammation. This contract marks a strategic move in the clinical trials sector, with Trellus TrialSet™ designed to improve participant readiness and retention through resilience-based methodologies. Additionally, Trellus Health has been granted preferred vendor status by another major CRO, reinforcing its position in the clinical trials vertical and providing access to a broader client base, although not immediately impacting revenue.
Trellus Health PLC has announced updates regarding its financial and operational strategies, including extending its cash runway to early December 2025 through cost-saving measures and reducing its monthly cash burn. The company is in late-stage contract negotiations for a collaboration with a leading global CRO, which could enhance its positioning in the clinical trials sector. Additionally, Trellus Health is exploring potential equity fundraising to support future growth, though no definitive funding transactions have been concluded yet.